XNASKRON
Market cap59mUSD
Jan 08, Last price
0.99USD
1D
-1.99%
1Q
0.51%
IPO
-96.60%
Name
Kronos Bio Inc
Chart & Performance
P/E
—
P/S
9.45
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.21%
Rev. gr., 5y
%
Revenues
6m
Net income
-113m
L-12.85%
CFO
-79m
L-13.58%
Earnings
Mar 19, 2025
Profile
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 6,288 | |||||
Cost of revenue | 128,118 | 141,578 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (121,830) | (141,578) | ||||
NOPBT Margin | ||||||
Operating Taxes | (3,911) | |||||
Tax Rate | ||||||
NOPAT | (121,830) | (137,667) | ||||
Net income | (112,673) -12.85% | (129,293) -13.28% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 1,105 | 1,231 | ||||
BB yield | -1.53% | -1.35% | ||||
| Debt | ||||||
Debt current | 5,786 | 2,347 | ||||
Long-term debt | 53,651 | 59,835 | ||||
Deferred revenue | 4,127 | |||||
Other long-term liabilities | 209 | |||||
Net debt | (115,549) | (195,527) | ||||
| Cash flow | ||||||
Cash from operating activities | (78,582) | (90,926) | ||||
CAPEX | (679) | (577) | ||||
Cash from investing activities | 66,368 | (32,222) | ||||
Cash from financing activities | 567 | 851 | ||||
FCF | (114,047) | (133,575) | ||||
| Balance | ||||||
Cash | 172,997 | 247,947 | ||||
Long term investments | 1,989 | 9,762 | ||||
Excess cash | 174,672 | 257,709 | ||||
Stockholders' equity | (508,783) | (396,923) | ||||
Invested Capital | 703,153 | 672,682 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 57,744 | 56,201 | ||||
Price | 1.25 -22.84% | 1.62 -88.08% | ||||
Market cap | 72,180 -20.72% | 91,046 -87.76% | ||||
EV | (43,369) | (104,481) | ||||
EBITDA | (119,694) | (139,312) | ||||
EV/EBITDA | 0.36 | 0.75 | ||||
Interest | 2,266 | |||||
Interest/NOPBT | ||||||